Two Sigma Advisers LP Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Two Sigma Advisers LP trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 45.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,330,500 shares of the biopharmaceutical company’s stock after selling 7,622,100 shares during the quarter. Two Sigma Advisers LP’s holdings in Pfizer were worth $247,538,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $27,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Performance

PFE opened at $22.83 on Monday. The firm has a market capitalization of $129.77 billion, a PE ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm has a 50 day moving average of $23.65 and a two-hundred day moving average of $25.32. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the company earned $0.82 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.54%. Pfizer’s payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.